Teladoc (TDOC) Stock
Key stats
- Market cap
- $1.63B
- Price / Earnings ratio
- -10.5x
- EPS (TTM)
- -$0.86
- Volume
- Loading
- 52-week high
- $9.89
- 52-week low
- $4.40
- EPS vs analyst estimate
- +16.7%Q3 FY25 · -$0.20 vs -$0.24
Source: third-party data provider, as of November 13, 2026
EPS estimate: analyst consensus
Compare with TDOC
Recent news
Teladoc Soars 26% as Revenue and Profit Beat Estimates; Hims & Hers Health and American Well Tick Up
Teladoc Soars 26% as Revenue and Profit Beat Estimates; Hims & Hers Health and American Well Tick Up
TDOC
Teladoc Health Q3 Earnings Call Highlights
Teladoc Health Q3 Earnings Call Highlights
TDOC
Teladoc: 3 Key Takeaways for Long-Term Investors
Teladoc: 3 Key Takeaways for Long-Term Investors
TDOC
Teladoc (TDOC) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Teladoc (TDOC) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
TDOCNews tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 68.07
- MACD 12/26/9
- 0.80
- EMA 9 of MACD
- 0.67
- MACD histogram
- 0.13
- SMA 50
- $6.67
- Price above SMA 50
- EMA 50
- $7.19
- Price above EMA 50
- SMA 200
- $6.58
- Price above SMA 200
- EMA 200
- $6.73
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Hold
Based on 8 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of -$0.19 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news
Teladoc Soars 26% as Revenue and Profit Beat Estimates; Hims & Hers Health and American Well Tick Up
Teladoc Soars 26% as Revenue and Profit Beat Estimates; Hims & Hers Health and American Well Tick Up
TDOCTeladoc Health Q3 Earnings Call Highlights
Teladoc Health Q3 Earnings Call Highlights
TDOCTeladoc: 3 Key Takeaways for Long-Term Investors
Teladoc: 3 Key Takeaways for Long-Term Investors
TDOCTeladoc (TDOC) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Teladoc (TDOC) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
TDOC
Teladoc (TDOC) Reports Q3 Loss, Beats Revenue Estimates
Teladoc (TDOC) Reports Q3 Loss, Beats Revenue Estimates
TDOC
Unveiling Teladoc (TDOC) Q3 Outlook: Wall Street Estimates for Key Metrics
Unveiling Teladoc (TDOC) Q3 Outlook: Wall Street Estimates for Key Metrics
TDOC
Teladoc (TDOC) Outperforms Broader Market: What You Need to Know
Teladoc (TDOC) Outperforms Broader Market: What You Need to Know
TDOC
Teladoc (TDOC) Rises As Market Takes a Dip: Key Facts
Teladoc (TDOC) Rises As Market Takes a Dip: Key Facts
TDOC
Teladoc Strengthens Solo Platform With New AI-Powered Care Tools
Teladoc Strengthens Solo Platform With New AI-Powered Care Tools
TDOC
Teladoc (TDOC) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Teladoc (TDOC) Sees a More Significant Dip Than Broader Market: Some Facts to Know
TDOCNews tone: automated (AI) classification of the article's content, not a price prediction.
About Teladoc
Teladoc Health is the global virtual care leader, helping millions of people resolve their healthcare needs with confidence. We have unified the combined capabilities and global market presence of our award-winning consumer experience brands to create the only comprehensive virtual care solution capable of serving organizations and people everywhere. Teladoc Health uses proprietary health signals and personalized interactions to drive better health outcomes across the full continuum of care, at every stage in a person’s health journey.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Charles Divita III, CPA | CEO & Director | 1970 |
| Mr. Michael Fitzgerald Grasher | Chief Financial Officer | 1965 |
| Mr. Adam Christian Vandervoort J.D. | Chief Legal Officer & Secretary | 1975 |
| Mr. Carlos Nueno | President of International | 1974 |
| Ms. Kelly M. Bliss | President of U.S. Group Health | 1975 |
| Dr. George Byron Brooks BS EE, M.D. | Co-Founder | — |
| Mr. Joseph Ronald Catapano Cpa | Senior VP & Chief Accounting Officer | 1969 |
| Mr. Dave Ross | Chief Technology Officer | — |
| Michael Minchak | Vice President of Investor Relations | — |
| Ms. Laura Whipple | Chief Communications & Brand Officer | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 68.07
- MACD 12/26/9
- 0.80
- EMA 9 of MACD
- 0.67
- MACD histogram
- 0.13
- SMA 50
- $6.67
- Price above SMA 50
- EMA 50
- $7.19
- Price above EMA 50
- SMA 200
- $6.58
- Price above SMA 200
- EMA 200
- $6.73
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
8 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $6.50
- Average
- $8.64
- High
- $10.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -25.0 | -1.7 | ||||||||||
| 2022 | -19.3 | -5.5 | -2.8 | -54.2 | -8.2 | +1.8 | +5.8 | -15.6 | -17.7 | +14.6 | -1.3 | -18.4 |
| 2023 | +30.2 | -13.8 | +0.1 | +3.6 | -14.5 | +6.3 | +16.2 | -18.4 | -18.7 | -10.3 | +8.9 | +13.6 |
| 2024 | -11.4 | -24.0 | +0.7 | -14.1 | -12.3 | -11.7 | +1.2 | -16.5 | +24.4 | +1.6 | +30.1 | -21.0 |
| 2025 | +6.7 | -4.9 | -15.6 | -7.3 | -1.0 | +26.8 | -16.0 | +11.4 | +1.2 | +10.6 | -6.8 | -5.9 |
| 2026 | -22.7 | -2.0 | +5.6 | +14.8 | +17.8 | +7.2 | -26.3 | -5.1 | -7.3 | +50.1 | +3.6 |
